section name header

Indications

High Alert

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypotension, peripheral vasoconstriction.

Derm: hyperpigmentation, mucocutaneous toxicity, alopecia, erythema, rash, urticaria, vesiculation.

GI: weight, anorexia, nausea, stomatitis, vomiting.

Hemat: anemia, leukopenia, thrombocytopenia.

Local: pain at tumor site, phlebitis at IV site.

Neuro: aggressive behavior, disorientation, weakness.

Resp: pneumonitis, PULMONARY FIBROSIS.
Misc: chills, fever, ANAPHYLACTOID REACTIONS.

Interactions

Drug-Drug:

Availability

(Generic available)

Route/Dosage

see Calculator

Patients with lymphoma should receive initial test doses of 2 units or less for the first 2 doses

Action

Therapeutic Effects:

Classifications

Therapeutic Classification: antineoplastics

Pharmacologic Classification: antitumor antibiotics

Pharmacokinetics

Absorption: IV administration results in complete bioavailability. Well absorbed from IM and SUBQ sites. Absorption follows intrapleural and intraperitoneal administration.

Distribution: Widely distributed; concentrates in skin, lungs, peritoneum, kidneys, and lymphatics.

Metabolism/Excretion: 60–70% excreted unchanged by the kidneys.

Half-life: 2 hr ( in renal impairment).

Time/Action Profile

(tumor response)

ROUTEONSETPEAKDURATION
IV, IM, SUBQ2–3 wkunknownunknown

Patient/Family Teaching

Pronunciation

blee-oh-MYE-sin